首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   12941篇
  免费   1246篇
  国内免费   323篇
耳鼻咽喉   172篇
儿科学   421篇
妇产科学   153篇
基础医学   1662篇
口腔科学   463篇
临床医学   789篇
内科学   1715篇
皮肤病学   69篇
神经病学   1878篇
特种医学   415篇
外国民族医学   3篇
外科学   1675篇
综合类   1052篇
现状与发展   2篇
预防医学   269篇
眼科学   2608篇
药学   505篇
  2篇
中国医学   232篇
肿瘤学   425篇
  2024年   24篇
  2023年   220篇
  2022年   280篇
  2021年   489篇
  2020年   534篇
  2019年   507篇
  2018年   529篇
  2017年   503篇
  2016年   490篇
  2015年   480篇
  2014年   750篇
  2013年   1007篇
  2012年   592篇
  2011年   653篇
  2010年   566篇
  2009年   569篇
  2008年   623篇
  2007年   615篇
  2006年   590篇
  2005年   462篇
  2004年   399篇
  2003年   381篇
  2002年   311篇
  2001年   278篇
  2000年   230篇
  1999年   186篇
  1998年   190篇
  1997年   182篇
  1996年   158篇
  1995年   155篇
  1994年   145篇
  1993年   134篇
  1992年   106篇
  1991年   123篇
  1990年   104篇
  1989年   77篇
  1988年   84篇
  1987年   78篇
  1986年   89篇
  1985年   104篇
  1984年   95篇
  1983年   73篇
  1982年   81篇
  1981年   66篇
  1980年   51篇
  1979年   32篇
  1978年   33篇
  1977年   29篇
  1976年   17篇
  1973年   9篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Survey of ophthalmology》2023,68(5):920-928
There remains limited agreement regarding the efficacy and safety of different antivascular endothelial growth factor (anti-VEGF) agents for the management of polypoidal choroidal vasculopathy (PCV). Our meta-analysis compares different anti-VEGF agents for PCV treatment. Ovid MEDLINE, EMBASE, and Cochrane Library were systematically searched from January 2000 to July 2022. We included articles comparing the efficacy and safety of different anti-VEGF agents, specifically bevacizumab (BEV), ranibizumab (RAN), aflibercept AFL), and brolucizumab (BRO), for patients with PCV. 10,440 studies were identified, 122 underwent full-text review, and seven were included. One study was a randomized trial, and six were observational studies. Ranibizumab and aflibercept were associated with a similar best-corrected visual acuity (BCVA) at the last visit in three observational studies (P = 0.10), similar retinal thickness at the last visit in two observational studies (P = 0.85). One observational study comparing BEV versus RAN found comparable outcomes for final BCVA, retinal thickness, and polyp regression. One randomized trial on BRO versus AFL found comparable outcomes for improvement in BCVA, while anatomical outcomes favored BRO. The available evidence suggests that final BCVA is comparable across different anti-VEGF agents, however, further investigation is warranted due to paucity of evidence.  相似文献   
2.
3.
4.
5.
6.
Adenoid cystic carcinoma (AdCC) is a salivary gland-type of cancer that may also occur in the breast. Breast AdCC shows the same morphological spectrum as is observed in salivary glands, with recognition of individual subtypes that may differ in their clinical behaviour. AdCC classic variant (C-AdCC) is a slowly growing tumour, with a low rate of axillary node and distant metastases. Local recurrences may develop as a consequence of incomplete surgical excision. C-AdCC should be differentiated from the solid-basaloid variant of AdCC (SB-AdCC) that is characterized by nuclear atypia, frequent mitotic figures and necrosis, in addition to the solid architecture. SB-AdCC is a more aggressive tumour, with higher rates of axillary node and distant metastases. AdCC may also co-exist with more aggressive types of carcinoma including metaplastic and neuroendocrine carcinoma, referred to as AdCC with high grade transformation (HG-AdCC). This paper reviews the key diagnostic criteria of the different subtypes of breast AdCC with emphasis on differential diagnosis and prognostic parameters.  相似文献   
7.
ObjectiveTo study the clinical features and identify unique renal neoplasia subtypes and their prognostic implications in individuals with tuberous sclerosis complex (TSC).Patients and MethodsThe Mayo Clinic nephrectomy registry included 37 patients with TSC diagnosed between 1970 and 2018. Four additional patients were identified from the pathology consultation and autopsy files. All available renal tumors were further characterized using immunohistochemistry and fluorescence in situ hybridization. Clinicopathologic features and follow-up were obtained from the medical record. The American Association for Cancer Research Project GENIE registry was accessed using cBioPortal for molecular profiling of angiomyolipoma (AML).ResultsA total of 276 renal tumors from 41 patients were analyzed. Renal tumors were classified into 9 distinct morphological subtypes, with AML predominating (238 [86%]). Interestingly, all these tumors acted in a benign fashion except one renal cell carcinoma with clear cells and fibromyomatous stroma and one epithelioid AML that metastasized. Molecular profiling studies revealed that epithelioid AMLs were enriched for alterations of TP53, RB1, and ATRX. Eight patients died of direct complications of TSC, including 3 of end-stage renal disease. To date, none have died of a renal epithelial neoplasm.ConclusionThe identification of unique renal neoplasia subtypes may provide important clues to establish a diagnosis of TSC, and in the somatic setting, this finding has important implications for accurate prognostication. These tumors tend to be indolent, and only 2 of 276 tumors in our study exhibited metastatic behavior. Our results support multidisciplinary management with a focus on preservation of renal function.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号